These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pancreatic cancer survival analysis defines a signature that predicts outcome. Raman P; Maddipati R; Lim KH; Tozeren A PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011 [TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. Sergeant G; van Eijsden R; Roskams T; Van Duppen V; Topal B BMC Cancer; 2012 Nov; 12():527. PubMed ID: 23157946 [TBL] [Abstract][Full Text] [Related]
6. Low expression of tRF-Pro-CGG predicts poor prognosis in pancreatic ductal adenocarcinoma. Li J; Jin L; Gao Y; Gao P; Ma L; Zhu B; Yin X; Sui S; Chen S; Jiang Z; Zhu C J Clin Lab Anal; 2021 May; 35(5):e23742. PubMed ID: 33675071 [TBL] [Abstract][Full Text] [Related]
7. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564 [TBL] [Abstract][Full Text] [Related]
8. A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. Newhook TE; Blais EM; Lindberg JM; Adair SJ; Xin W; Lee JK; Papin JA; Parsons JT; Bauer TW PLoS One; 2014; 9(9):e105631. PubMed ID: 25180633 [TBL] [Abstract][Full Text] [Related]
9. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307 [TBL] [Abstract][Full Text] [Related]
10. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S Front Immunol; 2021; 12():648917. PubMed ID: 33777046 [No Abstract] [Full Text] [Related]
11. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma. Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147 [TBL] [Abstract][Full Text] [Related]
12. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
13. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression. Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173 [TBL] [Abstract][Full Text] [Related]
14. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369 [TBL] [Abstract][Full Text] [Related]
15. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis. Shang M; Zhang L; Chen X; Zheng S Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587 [TBL] [Abstract][Full Text] [Related]
16. A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma. Sun X; Song H; Sun X; Liao C; Wang G; Xu Y; Li L; Han Y; Xu C; Wang W; Cai S; Liang H; Yu H Cancer Invest; 2024 Mar; 42(3):226-242. PubMed ID: 38616304 [TBL] [Abstract][Full Text] [Related]
17. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Fu XL; Liu DJ; Yan TT; Yang JY; Yang MW; Li J; Huo YM; Liu W; Zhang JF; Hong J; Hua R; Chen HY; Sun YW Sci Rep; 2016 Sep; 6():33535. PubMed ID: 27628540 [TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. Zhao L; Zhao H; Yan H BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660 [TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560 [TBL] [Abstract][Full Text] [Related]
20. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]